At ASCO, the CHRYSALIS-2 study read-out showed that patients on the combination had overall survival of nearly three-and-a-half years.

In combination with Keytruda, the antibody-drug conjugate slowed progression compared to anti-PD-1 therapy alone.

The trial missed its primary endpoint but showed the test can detect cancers earlier, fueling questions around the best framework to evaluate MCED tests.

NEW YORK – Natera and Diakonos Oncology on Friday announced a collaboration to use Natera's circulating tumor DNA (ctDNA) assay Signatera to longitudinally assess molecular response in Diakonos' Phase ...

The EXONERATE assay has demonstrated that it can predict outcomes and monitor resistance in colorectal cancer patients treated with EGFR inhibitors.

In addition to the beta-emitting yttrium-90 therapy, the company is also testing a yttrium-86 companion diagnostic in the Phase I trial.

The firm will evaluate its adeno-associated virus-based gene therapy, TGX-007, in patients with newly diagnosed or recurrent tumors.

Some patients have a mutation that causes them to not produce CA19-9, a tumor marker often used to help determine prognosis.

The firm will use proceeds from the offering to advance its late-stage pipeline of precision medicines for cardiovascular diseases.

NEW YORK – The US Food and Drug Administration has requested additional data from AstraZeneca for its new drug application seeking approval for camizestrant for breast cancer patients with ESR1 ...

The firm will evaluate the combination therapy in 80 patients with germline BRCA1/2-mutated HER2-negative locally advanced or metastatic breast cancer.